Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2005-07-13
2009-02-24
Salimi, Ali R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S069100
Reexamination Certificate
active
07494658
ABSTRACT:
Vaccine formulations comprising, viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed.
REFERENCES:
patent: 5618536 (1997-04-01), Lowy et al.
patent: 6066324 (2000-05-01), Gissmann et al.
patent: 6165471 (2000-12-01), Garcea et al.
patent: 6228368 (2001-05-01), Gissmann et al.
patent: 6352696 (2002-03-01), Hallek et al.
patent: 6562351 (2003-05-01), Hallek et al.
patent: 6599508 (2003-07-01), Gissmann et al.
patent: 6649167 (2003-11-01), Hallek et al.
patent: 7182947 (2007-02-01), Hallek et al.
patent: 2005/0031636 (2005-02-01), Gissman et al.
patent: 0 565 794 (1993-10-01), None
patent: 0 390 252 (1996-07-01), None
patent: 0 343 783 (2000-03-01), None
patent: WO 90/10459 (1990-09-01), None
patent: WO 93/00436 (1993-01-01), None
patent: WO 93/02184 (1993-02-01), None
patent: WO 93/20844 (1993-10-01), None
patent: WO 93/21958 (1993-11-01), None
patent: WO 94/00152 (1994-01-01), None
patent: WO 94/05792 (1994-03-01), None
patent: WO 94/20137 (1994-09-01), None
patent: WO 94/23037 (1994-10-01), None
patent: WO 96/00583 (1996-01-01), None
patent: WO 96/11272 (1996-04-01), None
patent: WO 96/11274 (1996-04-01), None
patent: WO 96/19496 (1996-06-01), None
patent: WO 96/29091 (1996-09-01), None
patent: WO 98/04705 (1998-02-01), None
Altmann et al., “Towards HPV Vaccination,”Viruses and Cancer, Eds. Minson et al., Cambridge University Press, 71-80 (1994).
Arbeit et al., “Progressive Squamous Epithelial neoplasia in K14-Human Papillomavirus Type 16 Transgenic Mice,”Journal Of Virology, vol. 68, pp. 4358-4368 (Jul. 1994).
Balsley et al., “Progress in the Development of Human Papillomavirus Vaccines for HPV-11 and HPV-16/18 and Mapping of a Critical neutralizing Epitope” Abstract from HPV 2000 Int. Papillomavirus Conf. 366.
Barbosa et al., “In Vitro Biological Activities of the E6 and E7 Genes Vary among Human Papillomaviruses of Differenct Oncogenic Potential,”Journal Of Virology, vol. 65 No. 1, pp. 292-298, (Jan. 1991).
Breitburd et al., “Immunization With Viruslike Particles From Cottontail Rabbit Papillomavirus (CRPV) Can Protect Against Experimental CRPV Infection”,J. Virol., 69: 3959-3963 (1995).
Campo, “Vaccination Against Papillomavirus in Cattle” inCurrent Top Microbiol. Immunol: Human Pathogenic Papillomaviruses, Ed. Zur Hausen, Springer Verlag, Berlin, 186: 255-266 (1994).
Carter et al., “Expression of Human Papillomavirus Proteins in YeastSaccharomyces cerevisiae ,” Virology, pp. 513-521 (1991).
Christensen et al., “Assembled Baculovirus-Expressed Human Papillomavirus Type 11 L1 Capsid Protein Virus-Like Particles Are Recognized by Neutralizing Monoclonal Antibodies and Induce High Titres of Neutralizing Antibodies,”J. Gen. Virol., 75: 2271-2276 (1994).
Christensen et al., “Human Papillomavirus Types 6 and 11 Have Antigenically Distinct Strongly Immunogenic Conformationally Dependent Neutralizing Epitopes,”Virology, 205: 329-335 (1994).
Crum et al., “Coexpression of the Human Papillomvirus Type 16 E4 and L1 Open Reading Frames in Early Cervical Neoplasia”Virology, Academic Press, 178: 238-246 (1990).
Crum et al., “Human Papillomavirus Type 16 and Early Cervical Neoplasia”N. Engl. J. Med., Boston, MA, 310: 880-883 (1984).
Harry et al., “A Safety and Immunogenicity Trial of a Human Papillomavirus Type 16 L1 Virus-Like Particle Vaccine in Healthy Young Adult Human Volunteers” Abstract from HPV 2000 Int. Papillomavirus Conf. 362.
Heim et al., “Serum IgG, IgM, and IgA Reactivity to Human Papillomavirus Types 11 and 6 Virus-Like Particles in Different Gynecologic Patient Groups,”J. Infect. Dis., 172: 395-402 (1995).
Hofmann et al., “Sequence Determination of Human Papillomavirus Type 6a and Assembly of Virus-Like Particles inSaccharomyces cerevisiae,” Virology, 209: 506-518 (1995).
Ikenberg, “Human Papillomavirus DNA in Invasive Genital Carcinomas” inGenital Papillomavirus Infections, Eds. Gross et al., 87-112 (1990).
Jochmus et al., “Chimeric Virus-Like Particles of the Human Papillomavirus Type 16 (HPV 16) as a Prophylactic and Therapeutic Vaccine”,Archives of Medical Research, 30: 269-274 (1999).
Jochmus-Kudielka et al., “Antibodies Against the Human Papillomavirus Type 16 Early Proteins in Human Sera: Correlation of Anti-E7 Reactivity with Cervical Cancer”J. Natl. Cancer Inst., 81: 1698-1704 (1989).
Karasuyama et al., “Establishment Of Mouse Lines Which Constitutively Secrete Large Quantities Of Interleukin 2, 3, 4 Or 5, Using Modified cDNA Expression Vectors”,Immunol, pp. 97-104 (1988).
Kaufmann et al., “HPV16 L1E7 Chimeric Virus-Like Particles Induce Specific HLA-Restricted T Cells In Human After In Vitro Vaccination”Int. J. Cancer, 92: 285-293 (2001).
Kaur et al., “Immortalization of Primary Human Epithelial Cells by Cloned Cervical Carcinoma DNA Containing Human Papillomavirus Type 16 E6/E7 Open Reading Frames”J. Gen. Virology, vol. 70, pp. 1261-1266 (1989).
Kirnbauer et al., “A Virus-Like Particle Enzyme-Linked Immunosorbent Assay Detects Serum Antibodies in a Majority of Women Infected With Human Papillomavirus Type 16,”J. Natl. Cancer Inst., 86: 494-499 (1994).
Kirnbauer et al., “Efficient Self-Assembly of Human Papillomavirus Type 16 L1 and L1-L2 into Virus-Like Particles,”Journal of Virology, vol. 67, No. 12, pp. 6929-6936 (Dec. 1993).
Kirnbauer et al., “Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic,”Proc. Natl. Acad. Science, vol. 89, pp. 12180-12184 (1992).
Le Cann et al., “Detection of Antibodies against Human Papillomavirus (HPV) Type 16 Virions by Enzyme-Linked Immunosorbent Assay Using Recombinant HPV 16 L1 Capsids Produced by Recombinant Baculovirus,”J. Clin. Microbiol., 33: 1380-1382 (1995).
Le Cann et al., “Self-Assembly of Human Papillomavirus Type 16 Capsids by Expression of the L1 Protein in Insect Cells,”FEMS Microb. Lett., 117: 269-274 (1994).
Liu et al., “Mucosal Immunization with Papillomavirus Virus-Like Particles Elicits Systemic and Mucosal Immunity in Mice,”Virology, 252: 39-45 (1998).
Lowy et al., “Genital Human Papillomavirus Infection,”Proc. Nat. Acad. Sci. USA, 91: 2436-2440 (1994).
Muller et al., “Chimeric papillomavirus-like Particles,”Virology, pp. 93-111 (1997).
Müller et al., “Papillomavirus Capsid Binding and Uptake by Cells from Different Tissues and Species,”J. Virol, 69: 948-954 (1995).
Nasseri et al., “Genetic Analysis of CRPV Pathogenesis: the L1 Open Reading Frame in Dispensable for Cellular Transformation But Is Required for Papilloma Formation”,Virology, Academic Press, 170: 321-325 (1989).
Nonnenmacher et al., “Serologic Response to Human Papillomavirus Type 16 (HPV-16) Virus-Like Particles in HPV-16 DNA-Positive Invasive Cervical Cancer and Cervical Intraepithelial Neoplasia Grade III Patients and Controls from Columbia and Spain,”J. Infect. Dis., 172: 19-24 (1995).
Paintsil et al.,Virology, vol. 223, pp. 238-244 (1996).
Parkin et al., “Estimates of the Worldwide Frequency of Sixteen Major Cancers in 1980”,Int. J. Cancer, Alan R. Liss, Inc., 41: 184-197 (1988).
Poland et al., “A Randomized, Double-Blind, Placebo-Controlled Trial of the Immunogenicity and Reactogenicity of a Novel HPV 16 Vaccine: Preliminary Results” Abstract from HPV 2000 Int. Papillomavirus Conf. 363.
Pushko et al., “Sequence Variation in the Capsid Protein Genes of Human Papillomavirus Type 16”J. Gen. Virol., 75: 911-916 (1994).
Rawls et al., “Chemical Synthesis of Human Papillomavirus Type 16 E7 Oncoprotein: Autonomous Protein Domains for Induction of Cellular DNA Synthesis and fortransActivation,”Journal
Burger Alexander
Hallek Michael
Foley & Lardner LLP
Medigene AG
Salimi Ali R.
LandOfFree
Papilloma virus truncated L1 protein and fusion protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Papilloma virus truncated L1 protein and fusion protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Papilloma virus truncated L1 protein and fusion protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4087238